{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:05:18Z","timestamp":1772697918936,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002836","name":"Chang Gung University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00428-025-04388-9","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T13:50:23Z","timestamp":1768657823000},"page":"557-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High incidence of intrahepatic cholangiocarcinoma in end-stage renal disease patients in Taiwan: analysis of a nationwide database with molecular insight of aristolochic acid exposure"],"prefix":"10.1007","volume":"488","author":[{"given":"Shih-Chiang","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian Yi-Feng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ching","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Yun","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huei-Chieh","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Han","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tse-Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuang-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta-Sen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Te","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwai-Fong","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9527-7576","authenticated-orcid":false,"given":"Chien-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"4388_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17:557\u2013588. https:\/\/doi.org\/10.1038\/s41575-020-0310-z","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4388_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. Lancet 397:428\u2013444. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7","journal-title":"Lancet"},{"key":"4388_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100505","volume":"7","author":"N Normanno","year":"2022","unstructured":"Normanno N, Martinelli E, Melisi D, Pinto C, Rimassa L, Santini D, Scarpa A (2022) Role of molecular genetics in the clinical management of cholangiocarcinoma. ESMO Open 7:100505. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100505","journal-title":"ESMO Open"},{"key":"4388_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003\u20131010. https:\/\/doi.org\/10.1038\/ng.3375","journal-title":"Nat Genet"},{"key":"4388_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","volume":"32","author":"TS Bekaii-Saab","year":"2021","unstructured":"Bekaii-Saab TS, Bridgewater J, Normanno N (2021) Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol 32:1111\u20131126. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.012","journal-title":"Ann Oncol"},{"key":"4388_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","volume":"73","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW (2020) Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol 73:170\u2013185. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.007","journal-title":"J Hepatol"},{"key":"4388_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030688","volume":"9","author":"S Massironi","year":"2020","unstructured":"Massironi S, Pilla L, Elvevi A, Longarini R, Rossi RE, Bidoli P, Invernizzi P (2020) New and emerging systemic therapeutic options for advanced cholangiocarcinoma. Cells 9:688. https:\/\/doi.org\/10.3390\/cells9030688","journal-title":"Cells"},{"key":"4388_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/ijms25010461","volume":"25","author":"W Andraus","year":"2024","unstructured":"Andraus W, Tustumi F, De Meira JD, Pinheiro RSN, Waisberg DR, Lopes LD, Arantes RM, Santos VR, De Martino RB, D\u2019Albuquerque LAC (2024) Molecular profile of intrahepatic cholangiocarcinoma. Int J Mol Sci 25:461. https:\/\/doi.org\/10.3390\/ijms25010461","journal-title":"Int J Mol Sci"},{"key":"4388_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091761","volume":"16","author":"SH Lee","year":"2024","unstructured":"Lee SH, Song SY (2024) Recent advancement in diagnosis of biliary tract cancer through pathological and molecular classifications. Cancers 16:1761. https:\/\/doi.org\/10.3390\/cancers16091761","journal-title":"Cancers"},{"key":"4388_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","volume":"40","author":"A Hayashi","year":"2016","unstructured":"Hayashi A, Misumi K, Shibahara J, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M (2016) Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am J Surg Pathol 40:1021\u20131030. https:\/\/doi.org\/10.1097\/PAS.0000000000000670","journal-title":"Am J Surg Pathol"},{"key":"4388_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091216","volume":"12","author":"S Tavolari","year":"2023","unstructured":"Tavolari S, Brandi G (2023) Mutational landscape of cholangiocarcinoma according to different etiologies: a review. Cells 12:1216. https:\/\/doi.org\/10.3390\/cells12091216","journal-title":"Cells"},{"key":"4388_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul A, Cutcutache I, Yong CH et al (2017) Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 7:1116\u20131135. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0368","journal-title":"Cancer Discov"},{"key":"4388_CR13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/ng.2806","volume":"45","author":"W Chan-On","year":"2013","unstructured":"Chan-On W, Nairismagi ML, Ong CK et al (2013) Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 45:1474\u20131478. https:\/\/doi.org\/10.1038\/ng.2806","journal-title":"Nat Genet"},{"key":"4388_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan6446","volume":"9","author":"AWT Ng","year":"2017","unstructured":"Ng AWT, Poon SL, Huang MN et al (2017) Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci Transl Med 9:eaan6446. https:\/\/doi.org\/10.1126\/scitranslmed.aan6446","journal-title":"Sci Transl Med"},{"key":"4388_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/path.6072","volume":"260","author":"SC Huang","year":"2023","unstructured":"Huang SC, Chang IY, Chang CJ et al (2023) Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. J Pathol 260:165\u2013176. https:\/\/doi.org\/10.1002\/path.6072","journal-title":"J Pathol"},{"key":"4388_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Yang YHK, Lai EC (2019) Taiwan\u2019s national health insurance research database: past and future. Clin Epidemiol 11:349\u2013358. https:\/\/doi.org\/10.2147\/CLEP.S196293","journal-title":"Clin Epidemiol"},{"key":"4388_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1021\/tx3000889","volume":"25","author":"BH Yun","year":"2012","unstructured":"Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, Bonala R, Johnson F, Dickman KG, Grollman AP, Turesky RJ (2012) Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography\/ion-trap mass spectrometry. Chem Res Toxicol 25:1119\u20131131. https:\/\/doi.org\/10.1021\/tx3000889","journal-title":"Chem Res Toxicol"},{"key":"4388_CR18","doi-asserted-by":"publisher","first-page":"828314","DOI":"10.3389\/fonc.2021.828314","volume":"11","author":"HY Lai","year":"2021","unstructured":"Lai HY, Wu LC, Kong PH, Tsai HH, Chen YT, Cheng YT, Luo HL, Li CF (2021) High level of aristolochic acid detected with a unique genomic landscape predicts early UTUC onset after renal transplantation in Taiwan. Front Oncol 11:828314. https:\/\/doi.org\/10.3389\/fonc.2021.828314","journal-title":"Front Oncol"},{"key":"4388_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.dnarep.2016.05.027","volume":"44","author":"TA Rosenquist","year":"2016","unstructured":"Rosenquist TA, Grollman AP (2016) Mutational signature of aristolochic acid: clue to the recognition of a global disease. DNA Repair 44:205\u2013211. https:\/\/doi.org\/10.1016\/j.dnarep.2016.05.027","journal-title":"DNA Repair"},{"key":"4388_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00648","volume":"10","author":"J Han","year":"2019","unstructured":"Han J, Xian Z, Zhang Y, Liu J, Liang A (2019) Systematic overview of aristolochic acids: nephrotoxicity, carcinogenicity, and underlying mechanisms. Front Pharmacol 10:648. https:\/\/doi.org\/10.3389\/fphar.2019.00648","journal-title":"Front Pharmacol"},{"key":"4388_CR21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1124\/dmd.105.008706","volume":"34","author":"H Dong","year":"2006","unstructured":"Dong H, Suzuki N, Torres MC, Bonala RR, Johnson F, Grollman AP, Shibutani S (2006) Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling\/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos 34:1122\u20131127. https:\/\/doi.org\/10.1124\/dmd.105.008706","journal-title":"Drug Metab Dispos"},{"key":"4388_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41568-022-00494-x","volume":"22","author":"S Das","year":"2022","unstructured":"Das S, Thakur S, Korenjak M, Sidorenko VS, Chung FF, Zavadil J (2022) Aristolochic acid-associated cancers: a public health risk in need of global action. Nat Rev Cancer 22:576\u2013591. https:\/\/doi.org\/10.1038\/s41568-022-00494-x","journal-title":"Nat Rev Cancer"},{"key":"4388_CR23","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.7150\/thno.56539","volume":"11","author":"J Lin","year":"2021","unstructured":"Lin J, Cao Y, Yang X et al (2021) Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics 11:4585\u20134598. https:\/\/doi.org\/10.7150\/thno.56539","journal-title":"Theranostics"},{"key":"4388_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006086","volume":"5","author":"SL Poon","year":"2013","unstructured":"Poon SL, Pang ST, McPherson JR et al (2013) Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 5:197ra101. https:\/\/doi.org\/10.1126\/scitranslmed.3006086","journal-title":"Sci Transl Med"},{"key":"4388_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006200","volume":"5","author":"ML Hoang","year":"2013","unstructured":"Hoang ML, Chen CH, Sidorenko VS et al (2013) Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med 5:197ra102. https:\/\/doi.org\/10.1126\/scitranslmed.3006200","journal-title":"Sci Transl Med"},{"key":"4388_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ et al (2020) The repertoire of mutational signatures in human cancer. Nature 578:94\u2013101. https:\/\/doi.org\/10.1038\/s41586-020-1943-3","journal-title":"Nature"},{"key":"4388_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061442","volume":"14","author":"L Ceci","year":"2022","unstructured":"Ceci L, Zhou T, Lenci I et al (2022) Molecular mechanisms linking risk factors to cholangiocarcinoma development. Cancers 14:1442. https:\/\/doi.org\/10.3390\/cancers14061442","journal-title":"Cancers"},{"key":"4388_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","volume":"57","author":"WC Palmer","year":"2012","unstructured":"Palmer WC, Patel T (2012) Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57:69\u201376. https:\/\/doi.org\/10.1016\/j.jhep.2012.02.022","journal-title":"J Hepatol"},{"key":"4388_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","volume":"72","author":"O Clements","year":"2020","unstructured":"Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA (2020) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 72:95\u2013103. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.007","journal-title":"J Hepatol"},{"key":"4388_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcjd.2020.09.008","volume":"45","author":"C Saengboonmee","year":"2021","unstructured":"Saengboonmee C, Seubwai W, Lert-Itthiporn W, Sanlung T, Wongkham S (2021) Association of diabetes mellitus and cholangiocarcinoma: update of evidence and the effects of antidiabetic medication. Can J Diabetes 45:282\u2013290. https:\/\/doi.org\/10.1016\/j.jcjd.2020.09.008","journal-title":"Can J Diabetes"},{"key":"4388_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7150\/jca.16550","volume":"8","author":"CC Chien","year":"2017","unstructured":"Chien CC, Han MM, Chiu YH, Wang JJ, Chu CC, Hung CY, Sun YM, Yeh NC, Ho CH, Lin CC, Kao HY, Weng SF (2017) Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan. J Cancer 8:9\u201318. https:\/\/doi.org\/10.7150\/jca.16550","journal-title":"J Cancer"},{"key":"4388_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/nar\/gkp815","volume":"38","author":"S Attaluri","year":"2010","unstructured":"Attaluri S, Bonala RR, Yang IY, Lukin MA, Wen Y, Grollman AP, Moriya M, Iden CR, Johnson F (2010) DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res 38:339\u2013352. https:\/\/doi.org\/10.1093\/nar\/gkp815","journal-title":"Nucleic Acids Res"},{"key":"4388_CR33","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/cells12232718","volume":"12","author":"T Mitaka","year":"2023","unstructured":"Mitaka T, Ichinohe N, Tanimizu N (2023) \u201cSmall hepatocytes\u201d in the liver. Cells 12:2718","journal-title":"Cells"},{"key":"4388_CR34","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.apsb.2021.11.011","volume":"12","author":"S Chen","year":"2022","unstructured":"Chen S, Dong Y, Qi X et al (2022) Aristolochic acids exposure was not the main cause of liver tumorigenesis in adulthood. Acta Pharm Sin B 12:2252\u20132267. https:\/\/doi.org\/10.1016\/j.apsb.2021.11.011","journal-title":"Acta Pharm Sin B"},{"key":"4388_CR35","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1038\/ncomms6135","volume":"5","author":"G Scelo","year":"2014","unstructured":"Scelo G, Riazalhosseini Y, Greger L et al (2014) Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun 5:5135. https:\/\/doi.org\/10.1038\/ncomms6135","journal-title":"Nat Commun"},{"key":"4388_CR36","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41586-024-07368-2","volume":"629","author":"S Senkin","year":"2024","unstructured":"Senkin S, Moody S, Diaz-Gay M et al (2024) Geographic variation of mutagenic exposures in kidney cancer genomes. Nature 629:910\u2013918. https:\/\/doi.org\/10.1038\/s41586-024-07368-2","journal-title":"Nature"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04388-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04388-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04388-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:10:15Z","timestamp":1772694615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04388-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4388"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04388-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Chang Gung Memorial Hospital, with approval number IRB no. 202000490B0.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Chien-Feng Li received honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from ACT Genomics, Amoy Dx, AstraZeneca, Boehringer Ingelheim, CHUGAI, Eli Lilly, Illumina, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, and Roche. Chien-Feng Li also received research funding from ACT Genomics, Amgen, AmoyDx, Eli Lilly, Feng Chi Biotech, Illumina, Kim Forest enterprise, Lih Pao Life Science, Merck, Novartis, Quark Biosciences, ThermoFisher; and served as advisor\/expert on the boards of Bayer, Johnson & Johnson, Kim Forest enterprise, Inti Labs, Lih Pao Life Science, and Pharus Diagnostics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}